TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
You may also be interested in...
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.